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Abstract
Objective
According to current data available, neuroblastoma is the most frequent 
extracranial solid tumor in infants and children; because of its relationship to the 
primitive sympathetic ganglia, it may progress or regress spontaneously to more 
malignant or benign forms of tumors, respectively. It is also an important cause 
of the Opsoclonus Myoclonus Ataxia Syndrome (OMAS), or the “dancing eyes” 
syndrome. The risk factor of neuroblastoma includes patient’s age at diagnosis; 
degree of tumor spread, and selected biologic variables such as serum LDH, 
urinary and serum catecholamines such as VMA and HVA, ploidy and MYC-
N copy numbers. So, detection of risk factors and risk directed therapy are the 
mainstay of patient management.
Materials & Methods 
For this study the records of 43 out of 46 patients, aged less than 14 years, admitted 
over 8 years (1996-2004), with the confirmed diagnosis of neuroblastoma or 
ganglioneuroblastoma were evaluated for full course of therapy and follow 
up.
Results 
Of the patient group, 60% were male and 40% female. The most frequent 
clinical stage was stage 3 (34.7%), followed with stage 4 (32.6%) and 2 (26%). 
Less than 2% of patients presented with pure neurologic symptoms and these 
responded well to treatment. Relapse was seen more frequently in stage 4 
patients and less in stage 4S. The OPEC protocol, started in 81% of patients, 
achieved a 54% response; on the other hand, in 15%, N6 was used, with the 
response rate of 40%. Patient data was analyzed and interpreted using SPSS 
software to reveal which clinical and biologic factors improve neuroblastoma 
outcome. 
Conclusion 
Staging and patients’ age at the time of diagnosis are the most important clinical 
factors to predict outcome, while primary tumor site and some biologic findings 
such as urinary VMA and serum LDH levels have a less important value
Keywords: Neuroblastoma, Malignancy, Chemotherapy, Prognosis, Adrenal, 
Children, Opsoclonus myoclonus
Introduction 
Neuroblastoma which is the most common extracranial solid tumor of childhood 
and the second most frequent solid tumor in infants, aged less than 2 years, arises 
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from primordial neural-crest cells and may populate 
the adrenal gland or sympathetic ganglia, and hence 
has varied clinical presentations and courses )1). A 
distinctive feature of this tumor is its ability to regress 
spontaneously to ganglioneuroma or progress to more 
aggressive forms such as ganglioneuroblastoma or 
neuroblastoma(1,2). The most common site of origin 
of this tumor is the abdominal cavity (near the adrenal 
gland) but it may be found in the chest, head and neck, 
pelvis, central nervous system or other sites (1). This 
tumor has a wide range of clinical manifestations related 
to its site of origin, biologic products or antitumoral 
antibodies which may cause myoclonic/opsoclonic 
symptoms in these patients.
Opsoclonus Myoclonus Ataxia Syndrome (OMAS)-
or “dancing eyes” syndrome-is a paraneoplastic or 
postinfectious movement disorder. The occurrence of 
opsoclonus in childhood is a remarkable clinical sign 
and should always prompt the search for a precipitating 
neural-crest tumour, particularly neuroblastoma. 
Although the syndrome is debilitating and typically leads 
to delayed motor development, it is often the cognitive 
and behavioural sequelae that are most important to 
patients and their parents. Presentation occurs typically 
in infancy and early childhood, most patients presenting 
between 6 and 36 months of age (1) Presentation with 
opsoclonus and myoclonus is characteristic of the 
syndrome and is a prerequisite for diagnosis. However, 
the accompanying symptoms of irritability and sleep 
disturbance often pose a difficult management problem. 
A diagnosis of OMAS results in the identification of a 
neural-crest tumour (commonly neuroblastoma) in about 
50% of cases; patients with OMAS rarely present with 
neuroblastoma as the primary feature. Survival rates at 
1 year in patients with OMAS and neuroblastoma are 
better than those for patients with neuroblastoma alone 
(3, 4).
Because of its malignant nature, the disease is widespread 
in most patients at diagnosis; hence diagnosing and 
treating patients early in infancy is critical and life saving 
(5). Over the past decade much research had been done 
on neuroblastoma to improve the clinician’s ability to 
predict the risk of relapse for neuroblastoma at the time 
of diagnosis. Classically, the patients’ age at diagnosis 
and its stage are the most important prognostic factors 
(6). However, other biologic features are also important 
in patients’ risk, such as histologic characteristics of 
tumor, MYCN copy number, serum LDH and urine and 
serum catecholamines level (7,8,9,10).
Different treatment protocols may be used based on 
the wide range of biologic and clinical findings in 
neuroblastoma. However, in spite of technological 
advances in modern medicine, the tools to detect some 
of these important prognostic factors are unavailable 
in developing countries, and treatment is carried out 
based on the previously mentioned risk factors. Risk 
directed therapy is hence implemented according to 
patient’s age at diagnosis, degree of tumor spread, and 
selected biologic variables such as serum ferritin and 
LDH, urine catecholamines level, tumoral calcification 
and if available MYC-N copy numbers and TRKA 
expression(11,12). These markers accompanied with 
histopathologic findings of the tumor (Schwanian stroma, 
ganglionic differentiation, and mitotic activity) have 
the most practical prognostic significance in treatment 
strategy planning (8).
In addition to distal short arm of the chromosome 
number 2 amplification (MYC-N amplification) and 
TRKA expression, deletion of 1p, 11q or unbalanced 
gain of 17q are also very important to predicting factors 
in prognosis. Other biologic markers such as serum LDH 
and Ferritin levels, urinary catecholamine excretion and 
presence of calcification in the tumor have less important 
values (13). On the other hand, presence of myoclonus/ 
opsoclonus symptom is a good predicting factor.
Patients and Methods
This study enrolled all children, aged less than 14 years old 
with diagnosis of neuroblastoma, ganglioneuroblastoma 
and ganglioneuroma managed in Mofid’s children 
hospital in Tehran, between 1996 and 2004. Patient 
diagnosis had been confirmed with an unequivocal 
pathology report or presence of neuroblasts in bone 
marrow aspiration or biopsy, in addition to increased 
urinary catecholamines. Evaluated clinical and biologic 
markers in this study were age, sex, primary site of the 
tumor, serum LDH and urinary catecholamine levels, 
intratumoral calcification, clinical stage of the tumor, 
the chemotherapeutic protocols used in these patients 
and their outcome. MYC-N amplification status was not 
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assessed because of the unavailability of FISH method 
during this study. Patients were mostly treated with two 
standard protocols, the OPEC and N6; for a minority, we 
used a combination of these. Response to therapy was 
documented as favorable (complete remission without 
significant complication) and unfavorable response 
(relapse or death during or after completion of treatment 
plan).
Results 
Forty-six patients with full criteria of neuroblastoma, 
managed at the Mofid Children’s hospital, over a 
period of 8 years, entered in our study; of these were 
excluded because they disagreed with the treatment 
strategy. Initial age of our patients were 3 months to 12 
years old with the mean age of 30.1 months (SD = 27.7 
mo.). They comprised of 28 boys and 18 girls in all age 
groups (Male/ Female = 1.6 / 1) with the peak of male 
predominance in the first year of life (M/F = 3:1). The 
most frequent stage of disease observed at diagnosis was 
stage 3, diagnosed in 16 patients (34.7%), followed by 
stage 4 in 15 (32.6%); on the other hand stage 1 was not 
diagnosed in any. As shown in table 1, the advanced stage 
of disease is more frequent in patients over 2 years old. 
One patient presented with opsoclonus and myoclonus 
symptoms without any abnormalities in brain CT scan. 
His presenting stage at diagnosis was 3, and he responded 
well to therapy.
Primary tumor site observed most commonly in adrenal 
gland, followed by bone marrow and retroperitonium 
(table 2); tumor site and relation to stage of disease are 
summarized in table 3.
High urinary catecholamines (Vanyl Mandelic Acid 
and Homo Vanilic Acid) were seen in 65%, and were 
not related to the patients’ stage or response to therapy; 
on the contrary, normal serum LDH level, seen in 30% 
of patients, was accompanied with a good response to 
therapy in 85.7%.
Histopathologically, favorable histology was detected in 
17%, while in the remaining 83% this was unfavorable. 
Neuroblastoma and ganglioneuroblastoma were 
detected in 89% and 11% of patients respectively, but no 
ganglioneuroma was found.
In those with histology of ganglioneuroblastoma, the 
response rate was good in 60% and poor in the remaining 
40%. However, a good response was seen in 46% with 
neuroblastoma pathology.
Following completion of chemotherapy (OPEC or N6 
protocols), the duration of which was between 18 months 
and 7 years (mean 3.8 years), we found a survival rate of 
14% in stage 4 and 100% in stage 4s. Stage 2 and 3 had 
survival rates of 75% and 53% respectively (table 4).
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Table 1: Stage of disease in patients in different age ranges
4s4321
       Stage 
Age          
3 (18.7%)2 (12.5%)7 (43%)4 (25%)0< 12 m
02 (25%)1 (12.5%)5 (62.5%)013-24 m
04 (58%)3 (42%)0025-36 m
04 (50%)2 (25%)2 (25%)037-48 m
03 (42%)3 (42%)1 (16%)0>48 m
3 (6.5%)15 (32.6%)16 (34.7%)12 (26%)0sum
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25 (54%)2 (66.6%)9(60%)9 (56.2%)5 (41.5%)0Adrenal
13 (28%)1 (33.3%)11(73.3%)01 (8.3%)0Bone marrow
5 (10.8%)04 (26.6%)01 (8.3%)0bone
3 (6.5%) 03 (20%)000liver
5 (10.8%)04 (26.6%)1  (6.2%)00brain
5 (10.8%)1 (33.3%)2 (13.3%)02 (16.5%)0Head & neck
8 (17.3%)03 (20%)2 (12.5%)3(25%)0
Posterior 
Mediastinal
10 (21.7%)1 (33.3%)2 (13.3%)5 (31.2%)2 (16.5%)0Retroperitoneal
1 (2.1%)1 (33.3%)0000Skin
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Table 4: Response rate according to patient stage of disease
SumPoor responseGood response
        Response rate
Stage
0001
12 (100%)3 (25%)9 (75%)2
14 (100%)6 (47%)8 (53%)3
14 (100%)12 (86%)2 (14%)4
3 (100%)03 (100%)4s
43 (100%)21 (48.8%)22 (51.2%)sum
Discussion
 Neuroblastoma is a malignant primordial neural-crest tumor,
 found almost always in children and infants. According to
 the children cancer group (CCG) report by Golden et.al, this
 tumor has a mean age of 22 months at presentation which is
 earlier than the (5,6) more recent report of 30.1 months(6).
 In the case of delayed diagnosis, disease stages become more
 advanced and the patients are older, so their prognoses are
 more guarded (1,2). SEER and NCI reports revealed that early
 screening programs may reasonable because the advanced
 stage of disease is more prevalent in unscreened cases, but
final prognoses did not change with screening(5,14,15,16
 ,17). In our study, 32% of all patients presented with stage
 4 which is lower than the SEER and NCI reports, 42% and
 45% respectively, but in patients over 12 months, our findings
 (43%) are comparable. Interestingly our observation revealed
 that later diagnosis was not accompanied with more stages 4
 of the disease. Overall in patients aged over 2 years, 86% of
patients had stage 3 and 4 of the disease.
 Anti tumor antibodies which react against the patient’s
 cerebellum, may cause opsoclonus/ myoclonus symptoms.
 Only one of our patients with this problem developed
 involuntary, rapid eye movement in all directional gaze
 (opsoclonus) and  irregular jerking of muscles of the limbs
 and trunk (myoclonic jerking). Although the patient’s tumor
 was cured, his neurologic symptoms persisted throughout
 the 12 months of follow up. Data report this to be a good
 prognostic factor that improves patients survival because of
 its good biologic factors and presence of antitumor antibodies
 (1). Usually several months are need for improvement of
 neurological symptoms, but sometimes, they may remain for
life.
 The disease presented more frequently in male patients than in
 female (M/F=3/2), and was more pronounced during the first
year of life (M/F=3/1).
 Children with neuroblastoma and opsoclonus-myoclonus
 syndrome have adverse long-term neurologic sequelae
 compared with those without opsoclonus-myoclonus
 syndrome. In a review of 23 cases of neuroblastoma and
 myoclonic encephalopathy, Senelick et al. observed a residual
 neurologic deficit in 82% and persistent mental retardation
 in 36%. Only 13% had no long-term central nervous system
 (CNS) abnormalities (19). Koh et al, monitored 10 such
 children. All had a favorable stage of neuroblastoma and all
 were disease free at the time of the report; however, all but
 one had significantly delayed development (20) Telander et al.
in a study of 10 children with neuroblastoma and opsoclonus-
 myoclonus syndrome demonstrated adverse neurologic
 sequelae in most of the patients. Eight had hyperactivity and
 irritability, three had psychomotor retardation, and one had
seizures and chorea (18,19,20).
The most prevalent site of involvement at time of presentation 
(54%) was the adrenal; we observed 78% entire abdominal 
involvement. Overall bone marrow was the second most 
common site of primary tumor involvement, observed in 28% 
of cases, but in patients over 1 and 2 years old this increased to 
37% and 45% respectively. Brodeur in his report noted to the 
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40% adrenal involvement in patients over than 12 months old 
(13). According to the POG and CCG reports, intrathoracic 
and head and neck tumors are more frequent in infants less 
than 24 months old (5,6).
Urinary catecholamine excretion showed no difference in those 
patients who responded to treatment and in non-responders. 
But low serum LDH levels correlated strongly with lower 
stages of disease. 
Three patients were not evaluated continuously and excluded 
from our observation. Of the remainder, 51% had good response 
with minimal treatment complications and no recurrences in 
the 18 months to 7 years of follow up. In a thorough evaluation, 
74% finished their full doses of chemotherapeutic regimens, 
but 31% had recurrences of disease between 4 to 18 months 
completion of therapy. In spite of alternative chemotherapeutic 
regimens, all patients with recurrent disease expired; 25% 
of total deceased patients, died during their initial treatment 
protocols (19.7% due to disease progression and 5.3% of 
treatment complications). 
Our initial treatment regimens consisted of OPEC in 81%, 
and N6 in 15%; the remainder received a combination of 
regimens. Of patients, in 26% who received OPEC protocol, 
recurred after completion of therapy and 20% expired during 
therapy (disease progression or treatment complication); good 
response was observed in 54% on the OPEC regimen. In the 
N6 protocol group, however, good response rates were seen in 
40%, treatment related death in 20% and recurrence in 40%.
Radiotherapy was not a routine treatment strategy in 
neuroblastoma but was used as a palliative modality in only 
2 patients without any change in their life span. Nor was stem 
cell transplantation performed in any patient. 
Because of the limitations of genetic study and FISH method, 
MYCN copy number and TRKA gene were not investigated.
One of the most important problems in patients’ management 
was the lack of responsibility in some patients to follow 
current regimens especially in recurrent or advanced stages 
of disease; no responses were seen in recurrent cases and all 
of them deceased because of their disease progression. In 
spite of chemotherapy, stem cell transplantation which is an 
alternative modality in the newest treatment strategies was not 
performed in our patients. In addition, MYC-N copy number 
studies should be checked routinely to manage patients as a 
risk related strategy (21,22,23).
As a major problem, MYC-N amplification and copy number 
was not applicable so treatment was only stage based; in 
addition, bone marrow transplantation which is one the most 
important treatment modality was not performed in any 
patients.
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